LI-RADS version 2018 in Patients with Prior History of Hepatocellular Carcinoma: Are LR4 Observations Enough for the Diagnosis of Recurrent HCC?
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: We evaluated the diagnostic performance of LI-RADS version 2018 using gadoxetic acid enhanced MRI for recurrent but untreated HCC in patients with prior history of HCC. Materials and Methods: We enrolled 50 consecutive patients who 1) prior history of treatment of HCC, 2) underwent liver surgery for radiological/clinical diagnosis of new HCC between 2013 to 2018, 3) had gadoxetic acid enhanced MRI within one month before surgery, and 4) did not have more than five HCCs or infiltrative tumors only. Two radiologists reviewed MRI and determined the presence of LR3, LR4 and LR5 observations except previously treated tumors based on LI-RADS version 2018 in consensus. We sub-classified LR4 into LR4m (LR4 with major features only) and LR4u (LR4 upgraded from LR3 by ancillary features). LR4u were further sub-classified into LR4ua (with arterial phase hyperenhancement) and LR4un (without arterial phase hyperenhancement). Results: PPV for LR5, LR4 and LR3 observations for recurrent HCC were 100%, 61.5% and 25.0%, respectively. 100% (3/3) of LR4m were HCC. However, PPV of LR4u was 56.5%. PPV of LR4ua and LR4un were 73.3% and 25.0%, respectively. Sensitivity of LR5 and LR5+LR4 observations as a diagnostic threshold were 32.1% and 89.3%, respectively. Sensitivity for LR5+LR4m+LR4ua observations for diagnosis of HCC were 83.7% and significantly superior to that of LR5 without significant deterioration of specificity (75.0%). Conclusion: In patients with prior history of HCC, LR4 observations by major features or with APHE may be regarded as recurrent HCCs given high sensitivity and comparable specificity/PPV to LR5 observations.
Abstract
Purpose: We evaluated the diagnostic performance of LI-RADS version 2018 using gadoxetic acid enhanced MRI for recurrent but untreated HCC in patients with prior history of HCC. Materials and Methods: We enrolled 50 consecutive patients who 1) prior history of treatment of HCC, 2) underwent liver surgery for radiological/clinical diagnosis of new HCC between 2013 to 2018, 3) had gadoxetic acid enhanced MRI within one month before surgery, and 4) did not have more than five HCCs or infiltrative tumors only. Two radiologists reviewed MRI and determined the presence of LR3, LR4 and LR5 observations except previously treated tumors based on LI-RADS version 2018 in consensus. We sub-classified LR4 into LR4m (LR4 with major features only) and LR4u (LR4 upgraded from LR3 by ancillary features). LR4u were further sub-classified into LR4ua (with arterial phase hyperenhancement) and LR4un (without arterial phase hyperenhancement). Results: PPV for LR5, LR4 and LR3 observations for recurrent HCC were 100%, 61.5% and 25.0%, respectively. 100% (3/3) of LR4m were HCC. However, PPV of LR4u was 56.5%. PPV of LR4ua and LR4un were 73.3% and 25.0%, respectively. Sensitivity of LR5 and LR5+LR4 observations as a diagnostic threshold were 32.1% and 89.3%, respectively. Sensitivity for LR5+LR4m+LR4ua observations for diagnosis of HCC were 83.7% and significantly superior to that of LR5 without significant deterioration of specificity (75.0%). Conclusion: In patients with prior history of HCC, LR4 observations by major features or with APHE may be regarded as recurrent HCCs given high sensitivity and comparable specificity/PPV to LR5 observations.
참고문헌 (23)
- Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- Global Burden of Disease Liver Cancer Collaboration, "The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level : results from the global burden of disease study 2015", JAMA Oncol, 3, pp.1683~1691 (2017)
- European Association for the Study of the Liver, "EASL clinical practice guidelines : management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
- Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC, "2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma", Korean Journal of Radiology, 20(7), pp.1042~1113 (2019), 대한영상의학회[DOI]
- Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma : 2018practice guidance by the American Association for the study of liver diseases", Hepatology, 68, pp.723~750 (2018)
- Omata M, "Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma : a 2017 update", Hepatol Int, 11, pp.317~370 (2017)
- "Core. pdf?la=en" (2020)[URL]
- Chen PJ, "Clonal origin of recurrent hepatocellular carcinomas", Gastroenterology, 96, pp.527~529 (1989)
- Cha C, "Predictors and patterns of recurrence after resection of hepatocellular carcinoma", J Am Coll Surg, 197, pp.753~758 (2003)
- Cucchetti A, "Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population", Ann Surg Oncol, 16, pp.413~422 (2009)
- Huang ZY, "Long-term outcomes of repeat hepatic resection in patients with recurrent hepatocellular carcinoma and analysis of recurrent types and their prognosis : a single-center experience in China", Ann Surg Oncol, 19, pp.2515~2525 (2012)
- Taura K, "Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection : an analysis of 610 patients over 16 years old", Ann Surg, 244, pp.265~273 (2006)
- Lee EC, "Survival analysis after liver resection for hepatocellular carcinoma : a consecutive cohort of 1002 patients", J Gastroenterol Hepatol, 32, pp.1055~1063 (2017)
- Minagawa M, "Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma", Ann Surg, 238, pp.703~710 (2003)
- 정용은, "Noninvasive Biomarker for Predicting Treatment Response to Concurrent Chemoradiotherapy in Patients with Hepatocellular Carcinoma", Investigative Magnetic Resonance Imaging, 23(4), pp.351~360 (2019), 대한자기공명의과학회
- Choi SH, "Liver Imaging Reporting and Data System v2014 with gadoxetate disodiumenhanced magnetic resonance imaging : validation of LIRADS category 4 and 5 criteria", Invest Radiol, 51, pp.483~490 (2016)
- Kim YC, "Intra-individual comparison of gadolinium-enhanced MRI using pseudo-goldenangle radial acquisition with gadoxetic acid-enhanced MRI for diagnosis of HCCs using LI-RADS", Eur Radiol, 29, pp.2058~2068 (2019)
- Min JH, "Magnetic resonance imaging with extracellular contrast detects hepatocellular carcinoma with greater accuracy than with gadoxetic acid or computed tomography", Clin Gastroenterol Hepatol, 18, pp.2091~2100 (2020)[DOI]
- Semaan S, "Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid", Eur Radiol, 30, pp.1020~1030 (2020)
- Lee YJ, "Hepatocellular carcinoma : diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis", Radiology, 275, pp.97~109 (2015)
- Hanna RF, "Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma", Abdom Radiol (NY), 41, pp.71~90 (2016)
- Hope TA, "Hepatobiliary agents and their role in LI-RADS", Abdom Imaging, 40, pp.613~625 (2015)
- In Kyung Park, "Pseudoglandular Formation in Hepatocellular Carcinoma Determines Apparent Diffusion Coefficient in Diffusion-Weighted MRI", Investigative Magnetic Resonance Imaging, 22(2), pp.79~85 (2018), 대한자기공명의과학회[DOI]